Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: corticosteroids

A New Approach to Fracture Prevention

Susan Bernstein  |  December 14, 2016

Glucocorticoids are widely prescribed by rheumatologists, and the effects of daily and cumulative doses of these drugs on bone mineral density (BMD) are important elements of a draft clinical guideline document presented on Nov. 13 at the 2016 ACR/ARHP Annual Meeting in Washington, D.C. Leaders of the ACR guideline project discussed their recommendations at the…

Filed under:Clinical Criteria/GuidelinesConditionsMeeting ReportsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:2016 ACR/ARHP Annual Meetingdraft clinical guidelinefracture risk factorsFracturesGlucocorticoid-Induced OsteoporosisGlucocorticoid-Induced Osteoporosis Prevention and Treatment: An Updated ACR Clinical GuidelineGlucocorticoidsOsteoporosis

FDA Update on Rituximab & Etanercept; Plus New ACP Gout Guideline

Michele B. Kaufman, PharmD, BCGP  |  November 30, 2016

The FDA is considering an application for subcutaneous rituximab and has approved an application for etanercept to treat pediatric patients with plaque psoriasis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesGout and Crystalline ArthritisPediatric Conditions Tagged with:American College of PhysiciansetanerceptFDAFood and Drug AdministrationGoutguidelinePediatricplaque psoriasisrituximab

Reinitiating TNF Blockers after Tuberculosis Treatment

Michele B. Kaufman, PharmD, BCGP  |  November 23, 2016

A retrospective study showed that patients who have rheumatic disease and develop tuberculosis may be able to resume anti-TNF therapy and other biologic agents…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabAnti-TNFetanerceptInfectioninfliximabrituximabTuberculosistumor necrosis factor inhibitorTumor Necrosis Factor–Alpha Inhibitor

Rheumatologists Should Discuss with Patients Use of Immunomodulatory Agents During Pregnancy

Kimberly Retzlaff  |  November 16, 2016

The decision to continue or discontinue immunomodulatory medications during pregnancy is a difficult one for both patients and physicians. On the one hand, when left untreated, rheumatic conditions can cause harm to an unborn child, as well as to the pregnant mother. On the other hand, medications can be harmful to a developing fetus. In…

Filed under:Practice Support Tagged with:discontinuationdrugimmunomodulatory agentMedicationpatient carepatient communicationpregnancyRheumatic Diseaserheumatologistrisk

Veteran Rheumatologist Dr. Raymond Scalettar Recounts 60 Years of Practice, Growth of Specialty

Carol Patton  |  November 16, 2016

“Yes sir.” That was the response of Raymond Scalettar, MD, DSc, FACP, when his commanding officer told him the U.S. Army wanted him to switch specialties—from gastroenterology to rheumatology. There was only one problem. Dr. Scalettar wasn’t exactly sure what that would entail. That was the mid-1950s. Back then, rheumatology was barely out of the womb. Residency…

Filed under:Profiles Tagged with:CareerDr. Raymond ScalettarMilitaryPracticerheumatologistrheumatologyspecialty

Systemic Corticosteroid Usage in Stage 4 Pulmonary Sarcoidosis Could Offer Little Benefit, Pose Significant Health Risk

Josna Haritha, MD, MPH, Derick N. Jenkins, MD, & Manpreet Malik, MBBS  |  November 16, 2016

Depending on stage, severity and rate of progression of disease, systemic corticosteroids are commonly used to treat pulmonary sarcoidosis. However, a review of the literature suggests they have limited usefulness in advanced stage IV pulmonary sarcoidosis. Once sarcoidosis has advanced to this degree, steroid use may unnecessarily expose a patient to life-threatening complications, as demonstrated…

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:ClinicalCorticosteroidshealth riskhemoptysishypertensionmycetomaspatient carepulmonary sarcoidosisResearchSteroidtherapyTreatmentusage

Not All Infectious Microorganisms Malign Human Immune System

Simon M. Helfgott, MD  |  November 16, 2016

Which came first? The infectious microorganism or a host’s immune resistance against it? Through the millennia, a raging battle has pitted the hordes of infectious agents surrounding us against, arguably, the most complex biologic structure ever created, the finely tuned human immune system. The stakes are high for both sides. For the infectious agent, an…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:autoimmunityDiseaseessential mixed cryoglobulinemiaHepatitis C virushuman microbiomeImmune SystemInfectionmicroorganism

Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results

Michele B. Kaufman, PharmD, BCGP  |  October 12, 2016

A study found that ixekizumab decreases disease activity and increases physical function in biologic-naive patients with active psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumab-attoIL-17ixekizumabPsoriatic Arthritis

Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

Alexey Fomin, MD, & W. Neal Roberts, MD  |  October 10, 2016

The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Lupus nephritispatient carepopulationpregnancyResearchrheumatologyriskSLEtacrolimustherapy

Anti-TNFs in Early Puberty May Improve Growth in Pediatric IBD

Reuters Staff  |  October 4, 2016

NEW YORK (Reuters Health)—Anti-TNF drugs are more likely to improve growth in children with inflammatory bowel disease (IBD) if they’re given in the earlier stages of puberty, new findings show.¹ Children who achieve remission are also more likely to have satisfactory growth, the research team reported online on Sept. 21 in the Journal of Pediatric…

Filed under:ConditionsDrug UpdatesOther Rheumatic ConditionsPediatric Conditions Tagged with:adalimumabanti-TNF agentCrohn's diseaseinflammatory bowel diseaseinfliximabPediatriculcerative colitis

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 44
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences